Media headlines about Ocular Therapeutix (NASDAQ:OCUL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocular Therapeutix earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.2046993615335 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Ocular Therapeutix (NASDAQ:OCUL) traded down $0.04 during midday trading on Friday, reaching $4.91. The company had a trading volume of 304,492 shares, compared to its average volume of 717,478. Ocular Therapeutix has a 52-week low of $3.30 and a 52-week high of $11.79. The firm has a market cap of $183.81, a P/E ratio of -2.15 and a beta of 1.53. The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39.
A number of analysts have recently commented on the company. Zacks Investment Research downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Guggenheim assumed coverage on Ocular Therapeutix in a report on Monday, October 23rd. They issued a “buy” rating and a $12.00 price target for the company. BTIG Research upgraded Ocular Therapeutix from a “neutral” rating to a “buy” rating in a report on Friday, January 19th. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Ocular Therapeutix in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $20.67.
In other news, insider Antony C. Mattessich acquired 21,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was bought at an average cost of $4.29 per share, with a total value of $90,090.00. Following the transaction, the insider now directly owns 21,000 shares in the company, valued at approximately $90,090. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel M. Bollag acquired 24,700 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was purchased at an average cost of $3.93 per share, with a total value of $97,071.00. Following the completion of the transaction, the insider now owns 24,700 shares in the company, valued at $97,071. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 50,500 shares of company stock valued at $206,361. 26.10% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/17/ocular-therapeutix-ocul-getting-somewhat-favorable-news-coverage-accern-reports.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.